Vanderhyden Lab

Barbara Vanderhyden profile picture

Contact Information

Barbara Vanderhyden, PhD
613-737-7700 ext. 70330
bvanderhyden@ohri.ca

Ottawa Hospital Research Institute
Centre for Cancer Therapeutics
501 Smyth Road
Box 926
Ottawa, ON K1H 8L6

Lab Members

group image

Current Members

current member
Ken Garson

Research Associate

Research Interests

  • Understanding the function(s) of GREB1 through discovery of its interactome
  • Developing strategies for multiplexing single-cell sequencing
  • and much, much more
current member
Elizabeth Macdonald
Senior Research Technician

Research Interests
  • The impact of genetic modifications on tumour initiation and progression in mouse models of ovarian cancer
  • Responsible for managing and maintaining  transgenic mouse lines
  • Managing the Ottawa Ovarian Cancer Tissue Bank (overseen by Dr. Vanderhyden), which involves collecting and processing ovarian tumour tissue and maintaining corresponding records
current member
Atefeh Abedini

Postdoctoral Fellow

Research Interests

  • Role of the WNT signalling pathway in ovulatory wound repair
  • Determining the role of Smarca4 in initiation of small cell carcinoma of the ovary (SCCOHT)
  • Generating a mouse model of SCCOHT
  • Role of the Hippo signalling pathway in ovarian cancer
current member
Galaxia Rodriguez

Postdoctoral Fellow

Research Interests

  • Enhancing ovarian cancer immunogenicity
  • Modification of oncolytic viruses to improve efficacy in ovarian cancers
  • Development and testing of novel immune therapies in models of ovarian cancer

current member
David Landry
Postdoctoral Fellow

Research Interests
  • Defining the roles of SMARCA4 and SMARCA2 in ovarian function and fertility
current member
Lauren Carter
PhD candidate

Research Interests
  • Why ovulation is a risk factor for ovarian cancer
  • How ovarian stem cells are regulated during ovulatory wound repair
  • How TGFβ1 regulates ovarian stem cells
current member
Curtis McCloskey
PhD candidate

Research Interests
  • The role of BRCA1 loss in the initiation of ovarian cancer
  • Determining why ovulation contributes to the risk of ovarian cancer
  • Identifying novel therapeutic targets using a spontaneously transformed model of ovarian cancer
current member
Pascale Robineau-Charette
PhD candidate

Research Interests
  • The role of FGL2 in in vitro models of placental development
  • Linking the roles of SNF2L(Smarca1) and FGL2 in reproductive tissues
  • Investigating how aberrant levels of FGL2 may be involved in the pathology of preeclampsia 
current member
David Cook
PhD candidate

Research Interests
  • Cancer cell plasticity
  • Transcriptional dynamics of the epithelial-mesenchymal transition in ovarian cancer
  • Computational methods for the analysis of high-throughput genomics data
current member
Laura Forrest

MD-PhD Candidate

Research Interests

  • The function of GREB1 in ovarian cancer progression in estrogen-dependent and -independent models
  • The clinical relevance of GREB1 as a potential biotherapeutic target
current member
Kristianne Galpin
PhD candidate

Research Interests
  • Understanding the tumour microenvironment in ovarian cancer
  • Investigating the role of FGL2 in ovarian cancer progression
  • Developing novel immunotherapies for treatment of ovarian cancer
current member
Melanie Grondin
MD-PhD candidate

Research Interests
  • The function of transglutaminase 2 (TG2) in ovarian cancer progression and chemoresistance
  • Establishing the feasibility of novel TG2 inhibitors in the treatment of ovarian cancer